

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jun 2026

The efficacy of synbiotic supplements containing *Bacillus coagulans* and inulin with low FODMAP diet compared with low FODMAP diet alone on inflammatory factors, clinical outcomes and quality of life in patients with irritable bowel syndrome

Protocol summary

Study aim

To investigate the efficacy of synbiotic supplements containing *Bacillus coagulans* and inulin with low FODMAP diet compared with low FODMAP diet alone on inflammatory factors, clinical outcomes and quality of life in patients with irritable bowel syndrome.

Design

Randomized Clinical Trial double blind

Settings and conduct

In this study, patients with irritable bowel syndrome referring to Taleghani Hospital, if they wish to participate in the study informed consent of them will be taken. Patients were randomized to receive a synbiotic containing *Bacillus coagulans* plus low FODMAP diet or low FODMAP diet (and placebo) for 8 weeks. Before and after the intervention blood and fecal samples will be collected and scores will be evaluated for the evaluation of IBS symptoms.

Participants/Inclusion and exclusion criteria

1) 18-65 years 2) Patients with irritable bowel syndrome, according to gastroenterologist diagnosed according to the ROME-IV criteria 3) lack of any organic intestinal disease (diagnosed by last 5 years ago colonoscopy) and intestinal infections (diagnosed by stool culture). 4) No medical history of chronic gastrointestinal and colorectal disease. Absence of any major bowel surgery 5) Absence of regular use of laxatives or antidiarrheal drugs

Intervention groups

Intervention group: will receive one synbiotic capsule containing *Bacillus coagulans* (0.1 g) and inulin (0.9 g) per day plus low FODMAP diet for 8 weeks. Control: will receive low FODMAP diet and placebo for 8 weeks

Main outcome variables

Abdominal pain intensity, Abdominal pain frequency, Abdominal distension, Satisfaction with bowel habits, Interference with community function, Defecation

frequency, Defecation consistency, Patient-rated Severity score, serum level of IL-6 and INF- γ

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20100524004010N27**

Registration date: **2018-12-13, 1397/09/22**

Registration timing: **retrospective**

Last update: **2018-12-13, 1397/09/22**

Update count: **0**

Registration date

2018-12-13, 1397/09/22

Registrant information

Name

Azita Hekmatdoost

Name of organization / entity

Shahid Beheshti University of Medical Sciences,
National Institute of Nutrition Research

Country

Iran (Islamic Republic of)

Phone

+98 21 2293 0824

Email address

hekmat@sina.tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2017-09-22, 1396/06/31

Expected recruitment end date

2018-10-22, 1397/07/30
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
The efficacy of synbiotic supplements containing Bacillus coagulans and inulin with low FODMAP diet compared with low FODMAP diet alone on inflammatory factors, clinical outcomes and quality of life in patients with irritable bowel syndrome
Public title
Effect of Bacillus coagulans and inulin compared with low FODMAP diet in treatment of IBS
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
18-65 years Patients with irritable bowel syndrome, according to gastroenterologist diagnosed according to the ROME- IV criteria (1.Improvement with defecation 2.Onset associated with a change in stool frequency 3.Onset associated with a change in stool form (appearance) At least three days a month, three months a year and no pathological findings in the clinical investigating) lack of any organic intestinal disease(diagnosed by last 5 years ago colonoscopy) and intestinal infections(diagnosed by stool culture). No medical history of chronic gastrointestinal and colorectal disease Absence of any major bowel surgery Absence of regular use of laxatives or antidiarrheal drugs No chronic use of antibiotics, corticosteroids and immunosuppressants No usage of drugs that modifying the digestive motility such as metoclopramide, cisapride, diphenoxylate,... No usage of drugs that increased bleeding of intestinal mucosa such as aspirin, warfarin, heparin,... No history of breast cancer in patient or in first-degree relatives of a person Absence of severe mental or behavioral disorder Absence of nicotine and its derivatives use in last 6 months No usage of NSAIDs and aspirin in last week (influence on gut permeability)
Exclusion criteria:
Life threatening symptoms Death Not agree to continue the study
Age
From **18 years** old to **65 years** old
Gender
Both
Phase
N/A
Groups that have been masked
No information
Sample size
Target sample size: **50**
Actual sample size reached: **50**
Randomization (investigator's opinion)
Randomized
Randomization description

The method use in this study to create a randomization process is simple randomization, so we utilize random number table. Beginning of the study, each person is randomly assigned to one of the 2 study groups according to the randomized distribution table.

Blinding (investigator's opinion)

Not blinded

Blinding description**Placebo**

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sci

Street address

West arghavan, Sanaat square, Farahzadi boulevard, Shahrake gharb

City

Tehran

Province

Tehran

Postal code

193954741

Approval date

2017-12-31, 1396/10/10

Ethics committee reference number

IR.SBMU.nnftri.Rec.1396.206

Health conditions studied**1****Description of health condition studied**

Irritable Bowel Syndrom

ICD-10 code

K58

ICD-10 code description

Irritable bowel syndrome

Primary outcomes**1****Description**

Abdominal pain intensity

Timepoint

Beginning and end of study

Method of measurement

Questionnaire

2

Description

Abdominal pain frequency

Timepoint

Beginning and end of study

Method of measurement

Questionnaire

3

Description

Abdominal distension

Timepoint

Beginning and end of study

Method of measurement

Questionnaire

4

Description

Satisfaction with bowel habits

Timepoint

Beginning and end of study

Method of measurement

Questionnaire

5

Description

Interference with community function

Timepoint

Beginning and end of study

Method of measurement

Questionnaire

6

Description

Defecation frequency

Timepoint

Beginning and end of study

Method of measurement

Questionnaire

7

Description

Defecation consistency

Timepoint

Beginning and end of study

Method of measurement

Questionnaire

Secondary outcomes

1

Description

Patient-rated Severity score

Timepoint

Beginning and end of the study

Method of measurement

Questionnaire

2

Description

IBS-SSS

Timepoint

Beginning and end of the study

Method of measurement

Questionnaire

3

Description

IL-6

Timepoint

Beginning and end of the study

Method of measurement

Enzymatic method using a kit

4

Description

INF- γ

Timepoint

Beginning and end of the study

Method of measurement

Enzymatic method using a kit

Intervention groups

1

Description

Intervention group: will receive one synbiotic capsule containing *Bacillus coagulans*(0.1) g and inulin(0.9 g) per day plus low FODMAP diet for 8 weeks

Category

Treatment - Other

2

Description

Control group: will receive low FODMAP diet and placebo (starch) for 8 weeks

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Taleqani Hospital

Full name of responsible person

Amir Sadeghi

Street address

Arabi Ave, Daneshjoo Blvd, Velenjak

City

Tehran

Province

Tehran
Postal code
1985711151
Phone
+98 21 2243 2560
Email
taleghanihospital@sbmu.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Afshin Zarghi
Street address
West arghavan, Sanaat square, Farahzadi boulevard,
Shahrake gharb
City
Tehran
Province
Tehran
Postal code
00
Phone
+98 21 23871
Email
A_hekmat2000@yahoo.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Shahid Beheshti University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact

Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Azita Hekmatdoost
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition

Street address

West arghavan, Sanaat square, Farahzadi boulevard,
Qods Town

City

Tehran

Province

Tehran

Postal code

00

Phone

+98 912 306 5084

Email

A_hekmat2000@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Azita Hekmatdoost
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
West arghavan, Sanaat square, Farahzadi boulevard,
Qods Town
City
Tehran
Province
Tehran
Postal code
00
Phone
+98 912 306 5084
Email
A_hekmat2000@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Khadijeh Abhari
Position
Postdoctoral Fellowship
Latest degree
Ph.D.
Other areas of specialty/work
Food safety and Health
Street address
No. 7, West Arghavan Ave., Farahzadi Blvd., Qods
Town,
City
Tehran
Province
Tehran

Postal code

00

Phone

+98 917 303 2478

Email

m65abhari@gmail.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

Because the participant's informations should remain confidential.

Study Protocol

Undecided - It is not yet known if there will be a plan to

make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available